| scholarly article | Q13442814 |
| P356 | DOI | 10.4088/JCP.08M04548 |
| P698 | PubMed publication ID | 19689920 |
| P50 | author | Guy M. Goodwin | Q5622285 |
| P2093 | author name string | Robin Emsley | |
| Frédéric Rouillon | |||
| Agomelatine Study Group | |||
| Sandra Rembry | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | major depressive disorder | Q42844 |
| placebo | Q269829 | ||
| P304 | page(s) | 1128-1137 | |
| P577 | publication date | 2009-08-11 | |
| P1433 | published in | The Journal of Clinical Psychiatry | Q7743563 |
| P1476 | title | Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial | |
| P478 | volume | 70 |
| Q34207131 | A benefit-risk assessment of agomelatine in the treatment of major depression |
| Q37846892 | A critical review of pharmacotherapy for major depressive disorder. |
| Q28648515 | A systematic review of agomelatine-induced liver injury |
| Q22305782 | A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation |
| Q28578183 | Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC |
| Q37254909 | Agomelatine as monotherapy for major depression: an outpatient, open-label study |
| Q28651498 | Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression |
| Q37931969 | Agomelatine for the treatment of major depressive disorder |
| Q38137187 | Agomelatine in depression |
| Q37724201 | Agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS study |
| Q28651497 | Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks |
| Q28274600 | Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness |
| Q33610031 | Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE |
| Q28686885 | Agomelatine in unipolar depression in clinical practice: a retrospective chart review |
| Q41602250 | Agomelatine versus Sertraline: An Observational, Open-labeled and 12 Weeks Follow-up Study on Efficacy and Tolerability. |
| Q24201746 | Agomelatine versus other antidepressive agents for major depression |
| Q38093228 | Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review |
| Q34122643 | Agomelatine, the first melatonergic antidepressant: discovery, characterization and development |
| Q35628386 | Agomelatine: a novel antidepressant |
| Q48718989 | Agomelatine: an antidepressant without deterioration of sexual response |
| Q37587162 | Agomelatine: efficacy at each phase of antidepressant treatment |
| Q84997101 | Agomelatine: protecting the CNS from the effects of stress |
| Q91751261 | Antidepressant Withdrawal and Rebound Phenomena |
| Q28236293 | Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies |
| Q57476908 | Anxiolytic properties of compounds that counteract oxidative stress, neuroinflammation, and glutamatergic dysfunction: a review |
| Q33595018 | Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways |
| Q38876395 | Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients |
| Q43432380 | Chronic dim light at night provokes reversible depression-like phenotype: possible role for TNF. |
| Q48846517 | Chronic stress and antidepressant agomelatine induce region-specific changes in synapsin I expression in the rat brain |
| Q35128588 | Circadian arrhythmia dysregulates emotional behaviors in aged Siberian hamsters |
| Q34999604 | Clinical studies on the efficacy of agomelatine on depressive symptoms |
| Q35169141 | Combination of agomelatine and bupropion for treatment-resistant depression: results from a chart review study including a matched control group. |
| Q48908223 | Comparative phenotypic and cytochemical characteristics of lymphocytes of Wistar rats and rats with genetic predisposition to catalepsy after retabolil administration |
| Q34040072 | Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials |
| Q48038510 | Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland |
| Q28764080 | Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults |
| Q97681346 | Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis |
| Q58175706 | Déprimer par les nombres |
| Q34714511 | Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece |
| Q33583450 | Efficacy and tolerability of agomelatine in the treatment of depression |
| Q28246147 | Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal |
| Q53091817 | Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. |
| Q38109799 | Influence of the modern light environment on mood |
| Q36096664 | Major depressive disorder: new clinical, neurobiological, and treatment perspectives |
| Q38126092 | Manipulating melatonin in managing mood |
| Q24187803 | Melatonin and agomelatine for preventing seasonal affective disorder |
| Q48330847 | Melatonin synergizes with citalopram to induce antidepressant-like behavior and to promote hippocampal neurogenesis in adult mice |
| Q37307160 | Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants |
| Q64090510 | Molecular basis for the association between depression and circadian rhythm |
| Q36748061 | Mood disorders, circadian rhythms, melatonin and melatonin agonists |
| Q34507177 | New targets for rapid antidepressant action |
| Q34186242 | Novel melatonin-based therapies: potential advances in the treatment of major depression |
| Q33716723 | Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. |
| Q38953673 | Pooled Analysis of Four Non-Interventional Studies: Effectiveness and Tolerability of the Antidepressant Agomelatine in Daily Practice |
| Q28088645 | Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials |
| Q26864049 | Profile of agomelatine and its potential in the treatment of generalized anxiety disorder |
| Q41025993 | Recognition and management of antidepressant discontinuation syndrome |
| Q26853509 | Review of pharmacological treatment in mood disorders and future directions for drug development. |
| Q37776073 | Review: Restoring circadian rhythms: a new way to successfully manage depression |
| Q37776074 | Review: The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission |
| Q37776075 | Review: The importance of early symptom relief in antidepressant treatment: focus on agomelatine |
| Q38033191 | Role of melatonin in mood disorders and the antidepressant effects of agomelatine |
| Q34143560 | Serotonin Receptors – From Molecular Biology to Clinical Applications |
| Q28281050 | Single-nucleotide polymorphisms and mRNA expression for melatonin synthesis rate-limiting enzyme in recurrent depressive disorder |
| Q21203936 | Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series |
| Q37958832 | The effects of agomelatine on sexual function in depressed patients and healthy volunteers |
| Q38170413 | The mechanism, efficacy, and tolerability profile of agomelatine |
| Q62373349 | The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT2C receptors |
| Q37007350 | The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice |
| Q42468823 | The novel antidepressant agomelatine normalizes hippocampal neuronal activity and promotes neurogenesis in chronically stressed rats. |
| Q38366416 | The use of agomelatine in OCD: effects on the motivational aspects and dysregulated circadian rhythms |
| Q37701381 | The use of antidepressants in clinical practice: focus on agomelatine |
| Q37881968 | Therapeutic options in treatment-resistant depression |
| Q41535764 | Treatment of anxiety disorders |
| Q38151453 | Weight considerations in psychotropic drug prescribing and switching |
| Q35560309 | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. |
| Q84665251 | ▼Agomelatine for major depressive episodes |
Search more.